Risk-Adapted Neoadjuvant Chemoradiotherapy in Rectal Cancer: Final Report of the OCUM Study.
Reinhard RuppertTheodor JungingerRainer KubeJoachim StrassburgAndreas LewinJoerg BaralChristoph A MaurerJoerg SauerJohannes Christian LauscherGuenther WindeRena ThomasmeyerSigmar StelznerCornelius BambauerSoenke ScheunemannAxel FaedrichDaniel WollschlaegerSusanne MerkelPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
The findings support the avoidance of nCRT in low-risk patients and suggest that in high-risk patients, neoadjuvant therapy should be intensified to improve prognosis.